Strategies and Challenges in Clinical Trials Targeting Human Aging

  title={Strategies and Challenges in Clinical Trials Targeting Human Aging},
  author={John C Newman and Sofiya Milman and Shahrukh K Hashmi and Steven N. Austad and James L. Kirkland and Jeffrey B. Halter and Nir Barzilai},
  journal={The Journals of Gerontology Series A: Biological Sciences and Medical Sciences},
  pages={1424 - 1434}
Interventions that target fundamental aging processes have the potential to transform human health and health care. A variety of candidate drugs have emerged from basic and translational research that may target aging processes. Some of these drugs are already in clinical use for other purposes, such as metformin and rapamycin. However, designing clinical trials to test interventions that target the aging process poses a unique set of challenges. This paper summarizes the outcomes of an… 

Figures from this paper

Development of clinical trials to extend healthy lifespan
Development of large-scale clinical trials designed to determine whether multiple age-related health conditions can be simultaneously alleviated with interventions targeting the underlying biology of aging are described.
Frameworks for Proof-of-Concept Clinical Trials of Interventions That Target Fundamental Aging Processes
This article summarizes the outcomes of an international meeting partly funded through the NIH R24 Geroscience Network, whose purpose was to generate concepts and frameworks for early, proof-of-concept clinical trials for therapeutic interventions that target fundamental processes of aging.
Drugs that target aging: how do we discover them?
Two representative case studies are considered: 1) rapamycin analogs and their effect on the mTORC1 pathway, and 2) small molecules that target and kill senescent cells.
Creating the Next Generation of Translational Geroscientists
The sixth retreat of the National Institute on Aging R24 Geroscience Network brought together basic scientists, gerontologists, clinicians, and clinical researchers to discuss how to identify, recruit, and train investigators who can perform early‐stage clinical trials in geroscience.
Health Benefits of Anti-aging Drugs.
The effects of different drugs reported to extend the lifespan in model organisms from round worms to rodents mainly target the master regulators of aging such as mTOR, FOXO and PGC1α, affecting autophagy, inflammation and oxidative stress.
In silico clinical trials for anti-aging therapies
It is proposed that stochastic biomathematical modeling and computational simulation platforms should be developed as in silico strategies to accelerate the performance of clinical trials targeting human aging, and to provide personalized approaches and robust biomarkers of healthy aging at the individual-to-population levels.
Aging: therapeutics for a healthy future
Translational Geroscience: Challenges and Opportunities for Geriatric Medicine
  • T. Gill
  • Medicine
    Journal of the American Geriatrics Society
  • 2019
A major impediment to evaluating promising geroscience therapeutics is the relative paucity of clinician investigators who have sufficient knowledge and expertise at the interface of clinical research, geriatric medicine, and aging biology.
Translating Measures of Biological Aging to Test Effectiveness of Geroprotective Interventions: What Can We Learn from Research on Telomeres?
A research agenda is suggested to advance translation of algorithm-based aging biomarkers: establish validity in young-adult and midlife individuals; test responsiveness to exposures that shorten or extend healthy lifespan; and conduct repeated-measures longitudinal studies to test differential rates of change.
Measuring biological aging in humans: A quest
Current research focuses on measuring the pace of aging to identify individuals who are “aging faster” to test and develop interventions that could prevent or delay the progression of multimorbidity and disability with aging.


Clinical trial designs for more rapid proof-of-principle and approval
A Trial for the ages.
An unprecedented clinical trial is proposed in which half the subjects would get a placebo and half would get an old drug for type 2 diabetes called metformin, which has been shown to modify aging in some animal studies.
mTOR inhibition improves immune function in the elderly
MTOR inhibition by RAD001 improves immune responses in elderly volunteers receiving an influenza vaccination, raising the possibility that mTOR inhibition may have beneficial effects on immunosenescence in the elderly.
The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging.
Bioenergetics and mitochondrial dysfunction in aging: recent insights for a therapeutical approach.
The novel mitochondria targeted therapies and the new selective molecules and nanocarriers technology as potentially effective in targeting mitochondrial dysfunction and diseases involving oxidative stress and metabolic failure are focused on.
Calorie restriction and dietary restriction mimetics: a strategy for improving healthy aging and longevity.
Calorie restriction with adequate nutrition is the only non-genetic, and the most consistent non-pharmacological intervention that extends lifespan in model organisms from yeast to mammals, and protects against the deterioration of biological functions, delaying or reducing the risk of many age-related diseases.
Rapalogs and mTOR inhibitors as anti-aging therapeutics.
The prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling are discussed.
Promoting Health and Longevity through Diet: From Model Organisms to Humans